register

News & Trends - MedTech & Diagnostics

Novel tech to enhance brain tumour imaging and diagnosis

Health Industry Hub | May 13, 2021 |

MedTech News: A collaborative research program using combined technologies to improve brain tumour imaging and diagnosis is announced by Imagion Biosystems, a company dedicated to improving healthcare through the earlier detection of cancer, and Patrys, a therapeutic antibody development company.

Patrys’ novel deoxymabs are attracted to the DNA fragments released from dying tumour cells and are able to penetrate and kill tumour cells. The collaboration aims to pair the targeting specificity of the deoxymabs with the imaging capabilities of the MagSense technology to provide a highly effective imaging agent with high specificity for hard-to-diagnose cancers such as brain cancer.

“We are very interested in the tumour targeting capabilities of the Patrys deoxymabs and believe there is potential for Patrys’ deoxymabs to be paired with our MagSense nanoparticles for many types of solid tumors,” said Bob Proulx, Executive Chairman of Imagion Biosystems.

“Initially, we are very keen to investigate the potential for brain tumour imaging since there is such a high unmet need for differentiating cancerous tumours in the brain, like glioblastoma, as well as metastatic disease that has spread to the brain from other primary tumours.

“The combination of our two company’s technologies offers a range of exciting opportunities”, said Dr. James Campbell, Patrys’ CEO and Managing Director. “The potential for our deoxymab antibodies to home in on a range of different cancer types due to their affinity for DNA is one of the properties that makes them so unique and opens up a range of different clinical applications for their use.

“We are very excited to be further leveraging the cancer-targeting ability deoxymabs by partnering with Imagion and its innovative MagSense® imaging technology to potentially develop new ways to visualize and diagnose cancer.”

Preliminary research efforts by Imagion have demonstrated that the Patrys PAT-DX1 molecule can be conjugated to the MagSense nanoparticles and provide bio-functionality for targeting certain cancer cell lines. Should this further collaborative work provide positive results, Imagion will have an exclusive option to a future license agreement, should it elect to commercialize the imaging agent. Under the current collaboration both parties are bearing their own costs.

Brain tumours are neoplasms arising from cells of the central nervous system (CNS) including primary tumours originating in the brain and secondary tumours arising from metastases to the brain. Secondary brain tumours are significantly more frequent, affecting one in four cancer patients.

Of the more than 300,000 individuals afflicted with malignant brain cancer each year globally, less than 25% survive beyond five years. Conventional MRI has been the standard modality to identify and localise tumours in the brain for many years, but a biopsy is the only definitive way they can be diagnosed and two-thirds of primary brain tumours are benign. A non-invasive imaging method able to specifically identify malignant brain tumours and differentiate from benign disease would address a significant unmet medical need.


News & Trends - Pharmaceuticals

March PBAC agenda unveiled amid tensions over 'unprecedented' volume of submissions

March PBAC agenda unveiled amid tensions over ‘unprecedented’ volume of submissions

Health Industry Hub | November 29, 2024 |

The Department of Health has released the agenda for the March 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting, unveiling plans […]

More


News & Trends - MedTech & Diagnostics

Johnson & Johnson MedTech exits DePuy Synthes spine portfolio

J&J MedTech exits DePuy Synthes spine portfolio

Health Industry Hub | November 29, 2024 |

Johnson & Johnson MedTech will officially exit the DePuy Synthes Spine portfolio in Australia tomorrow, November 30, as part of […]

More


News & Trends - Pharmaceuticals

Home-grown hypertension polypill heads for regulatory approval

Home-grown hypertension polypill heads to regulatory approval

Health Industry Hub | November 29, 2024 |

Australian-supported research has revealed remarkable Phase III clinical trial results for an innovative triple drug combination in the treatment of […]

More


News & Trends - Pharmaceuticals

Will Australia become first country to eliminate HIV transmission by 2030?

Will Australia become first country to eliminate HIV transmission by 2030?

Health Industry Hub | November 29, 2024 |

In the lead-up to World AIDS Day on December 1, the Albanese Government has unveiled the 9th National HIV Strategy, […]

More


This content is copyright protected. Please subscribe to gain access.